Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.93 Insider Own10.42% Shs Outstand28.68M Perf Week3.02%
Market Cap18.61M Forward P/E- EPS next Y-0.28 Insider Trans0.00% Shs Float25.69M Perf Month8.27%
Income-83.99M PEG- EPS next Q-0.32 Inst Own9.35% Short Float1.45% Perf Quarter13.40%
Sales9.41M P/S1.98 EPS this Y68.94% Inst Trans-21.79% Short Ratio0.88 Perf Half Y18.00%
Book/sh-0.22 P/B- EPS next Y77.24% ROA-81.40% Short Interest0.37M Perf Year-78.15%
Cash/sh0.44 P/C1.48 EPS next 5Y- ROE-419.59% 52W Range0.45 - 3.47 Perf YTD10.47%
Dividend Est.- P/FCF- EPS past 5Y27.00% ROI- 52W High-81.30% Beta2.00
Dividend TTM- Quick Ratio0.21 Sales past 5Y129.46% Gross Margin-48.50% 52W Low44.22% ATR (14)0.04
Dividend Ex-Date- Current Ratio0.34 EPS Y/Y TTM50.24% Oper. Margin-505.33% RSI (14)56.07 Volatility4.44% 5.98%
Employees138 Debt/Eq- Sales Y/Y TTM553.09% Profit Margin-892.47% Recom2.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q77.41% Payout- Rel Volume0.12 Prev Close0.63
Sales Surprise-57.43% EPS Surprise-3.77% Sales Q/Q150.31% EarningsMay 15 AMC Avg Volume424.26K Price0.65
SMA206.04% SMA505.03% SMA200-7.21% Trades Volume50,733 Change3.02%
Date Action Analyst Rating Change Price Target Change
Nov-11-22Downgrade Raymond James Strong Buy → Outperform $5 → $2
Dec-29-21Resumed Jefferies Buy $7 → $6
Feb-25-21Initiated Jefferies Buy $7
Aug-27-20Upgrade Raymond James Outperform → Strong Buy $8 → $9
Jan-16-19Initiated Oppenheimer Outperform $9
Nov-01-17Initiated Canaccord Genuity Buy $10
Oct-10-16Initiated Laidlaw Buy $6
Jul-26-16Initiated Ladenburg Thalmann Buy
May-07-15Initiated Noble Financial Buy $7
May-22-24 08:00AM
May-15-24 09:54PM
Apr-16-24 01:52PM
04:05PM Loading…
Apr-11-24 04:05PM
Apr-09-24 02:45PM
Apr-03-24 08:00AM
Apr-02-24 08:00AM
Mar-22-24 07:00AM
Feb-14-24 12:48PM
Feb-13-24 07:04PM
Nov-20-23 08:00AM
Nov-14-23 04:05PM
08:00AM Loading…
Oct-26-23 08:00AM
Sep-27-23 07:30AM
Sep-07-23 08:00AM
Sep-06-23 08:00AM
Aug-14-23 08:00AM
Aug-03-23 06:25PM
Jul-24-23 08:00AM
Jul-19-23 08:00AM
Jul-13-23 07:00AM
Jul-06-23 09:00AM
Jul-05-23 04:12PM
Jun-23-23 04:05PM
Jun-15-23 08:00AM
Jun-07-23 08:00AM
09:32AM Loading…
Jun-04-23 09:32AM
May-15-23 09:25AM
May-03-23 10:00AM
May-01-23 10:00AM
Apr-25-23 08:00AM
Apr-05-23 11:42AM
Apr-04-23 01:55PM
Mar-15-23 06:37AM
Mar-13-23 09:15AM
Feb-23-23 08:00AM
Feb-15-23 08:00AM
Jan-24-23 06:16AM
Dec-08-22 08:00AM
Dec-06-22 09:25AM
Nov-22-22 08:00AM
Nov-14-22 08:00AM
Nov-11-22 08:00AM
Nov-10-22 09:15AM
Nov-08-22 06:25PM
Nov-03-22 06:35PM
Oct-17-22 08:00AM
Oct-13-22 11:23AM
Oct-12-22 10:38AM
Sep-29-22 08:00AM
Sep-21-22 08:00AM
Sep-15-22 08:30AM
Sep-08-22 01:00AM
Aug-08-22 09:15AM
Aug-04-22 08:25AM
Jul-19-22 09:25AM
Jul-14-22 12:30PM
Jul-12-22 08:00AM
Jun-28-22 08:00AM
Jun-22-22 04:06PM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
Jun-01-22 08:00AM
May-26-22 08:00AM
May-19-22 08:00AM
May-12-22 07:12AM
May-09-22 09:15AM
May-05-22 05:55PM
May-02-22 08:00AM
Apr-28-22 08:00AM
Apr-11-22 12:19PM
Apr-05-22 12:20PM
Mar-29-22 08:00AM
Mar-15-22 08:00AM
Mar-07-22 09:15AM
Feb-25-22 08:30AM
Feb-23-22 04:05PM
Feb-09-22 12:06PM
Jan-26-22 08:00AM
Jan-19-22 08:04PM
Jan-05-22 08:00AM
Dec-29-21 10:53AM
Dec-09-21 08:00AM
Dec-07-21 07:25AM
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILLIS STEVENDirectorJul 10 '23Buy1.65609,0901,004,9981,043,292Jul 18 09:00 AM